Matthias Herz

Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study

Robert R. Henry, A. Michael Lincoff, Sunder Mudaliar et al. · The Lancet · 2009 · 204 citations

Medicine, Endocrinology, Pharmacology +17

Treating hypertension with a device that slows and regularises breathing: a randomised, double-blind controlled study

MH Schein, B. Gavish, Matthias Herz et al. · Journal of Human Hypertension · 2001 · 171 citations

Medicine, Cardiology, Pharmacotherapy +8

Effect of Pioglitazone Compared with Metformin on Glycemic Control and Indicators of Insulin Sensitivity in Recently Diagnosed Patients with Type 2 Diabetes

Imre Pávó, György Jermendy, Tamás Várkonyi et al. · The Journal of Clinical Endocrinology & Metabolism · 2003 · 164 citations · Full text

Medicine, Endocrinology, Pharmacology +17

A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus

Matthias Herz, Don Johns, Jesús Reviriego et al. · Clinical Therapeutics · 2003 · 132 citations

Medicine, Pharmacology, Pharmacotherapy +11

Assessment of diabetic neuropathy: Definition of normal and discrimination of abnormal nerve function

Detlef Claus, Constanze Mustafa, Wilfried Vogel et al. · Muscle & Nerve · 1993 · 127 citations

Medicine, Neurology, Neuroscience +17